Brooks Laboratories Limited — Others, 29-05-2025: Copy of Newspaper Publication

Brooks Laboratories has announced a board meeting to consider the financial results for the quarter and half-year. The company delivered improved operational performance driven by higher volumes and an enhanced product mix. Steady growth across pharma formulations and contract manufacturing was supported by strong demand. Effective cost optimization helped sustain margins amid input cost pressures. The focus remains on capacity expansion and new product launches to reinforce market position, reflecting ongoing business momentum and initiatives aimed at boosting shareholder value.